Chemotherapy News and Research

Latest Chemotherapy News and Research

Mesupron could extend progression-free survival for metastatic breast cancer patients

Previous research has shown that a family of genes, proteins and enzymes called the uPA system (for urokinase plasminogen activator) plays an active role in different facets of cancer's biology, including tumor cell invasion, the spread of metastases, and the growth of a primary tumor. Mesupron- is a new small molecule inhibitor, taken as a pill, that inhibits the uPA system.

10 Dec 2012

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.

10 Dec 2012

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.

9 Dec 2012

Anti-seizure drug benefits women with severe morning sickness

Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a University at Buffalo professor who is conducting research on a drug that is showing success treating pregnant women with this condition.

8 Dec 2012

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results from the first large, global Phase III study of Halaven (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

7 Dec 2012

Blocking specific protein increases vulnerability of tumors to treatment

Blocking a specific protein renders tumors more vulnerable to treatment in mice, suggesting new therapies could eventually achieve the same in humans, according to new research from Fox Chase Cancer Center to be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium on Friday, December 7, 2012.

7 Dec 2012

Genomic tests increase accuracy of breast cancer diagnosis

The latest generation of genomic tests for breast cancer can improve physicians' ability to diagnose the disease and more precisely tailor each patient's treatment, according to a study being presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The study examined the first commercially available genomic tests to determine the molecular subtype of a breast cancer tumor.

7 Dec 2012

Diabetes drug may improve ovarian cancer survival

Women with ovarian cancer who are also receiving metformin for diabetes have significantly improved survival rates compared with their counterparts without diabetes, study findings show.

7 Dec 2012

Roundup: Fla. judge rules legislature must decide on prison care privatization; Skepticism over Ore. medical liability reform proposal

A Tallahassee judge ruled Tuesday that a legislative committee did not have the authority to approve a contract regarding prison health care services. According to Businessweek, the plan would privatize health care services in three of Florida's four prison system regions. Circuit Judge John Cooper, who made the decision, said the policy changes must be approved by the full Legislature, rather than just a panel of 14 select legislators.

6 Dec 2012

RedHill Biopharma completes $6.5M private placement

RedHill Biopharma Ltd., an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million.

6 Dec 2012

Targeted therapy as common as chemotherapy at end of life

Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.

6 Dec 2012

Using Nanoparticles to Target Cancer

An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.

6 Dec 2012

SLN surgery identifies whether breast cancer in lymph nodes remains after chemotherapy

Most patients whose breast cancer has spread to their lymph nodes have most of the lymph nodes in their armpit area removed after chemotherapy to see if any cancer remains. A study conducted through the American College of Surgeons Oncology Group and led by Judy Boughey, M.D. a breast surgeon at Mayo Clinic shows that a less invasive procedure known as sentinel lymph node surgery successfully identified whether cancer remained in lymph nodes in 91 percent of patients with node-positive breast cancer who received chemotherapy before their surgery.

6 Dec 2012

Study provides important data about fertility window of women with childhood cancer

This study provided important data about the fertility window of women who had suffered from childhood cancer and information concerning the associated risk factors, but did not confirm the greater risk of premature menopause (before the age of 40) that was reported by the American studies.

5 Dec 2012

Nanoparticle-based drug delivery attacks cancer cells without harming normal ones

This month, Molecular Pharmaceutics reported promising findings from the Nemours Center for Childhood Cancer Research and the Materials Science and Engineering Department at the University of Delaware, about the potential for nanotechnology to deliver chemotherapeutic agents in a way that attacks cancer cells without harming healthy cells.

5 Dec 2012

Researchers investigate GPER receptor as possible new drug target for breast cancer

Five-year breast cancer survival rates have improved dramatically over the past 50 years, but tumors can recur up to ten or more years after they are detected. When tumors recur, they are even more difficult to treat.

5 Dec 2012

Study calls for reform of Medicare reimbursement rates and hospice eligibility requirements

In the first national survey of enrollment policies at hospices, researchers from Mount Sinai School of Medicine and Yale University have found that the vast majority of hospices in the United States have at least one enrollment policy that could restrict access for terminally ill Medicare patients with high-cost medical needs.

5 Dec 2012

Combining 5-fluorouracil and IL-1 beta inhibitor can improve effectiveness of chemotherapy

These results reveal how the immune system can then limit the effectiveness of some cancer chemotherapies. The researchers now intend to block the molecules responsible for negative immune system activation to increase the efficiency of chemotherapy. A clinical trial to test this hypothesis should begin very soon.

5 Dec 2012

Data from OncoSec Medical clinical studies to be presented at DNA Vaccines 2012 Conference

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference.

4 Dec 2012

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.

3 Dec 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Mesupron could extend progression-free survival for metastatic breast cancer patients

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Anti-seizure drug benefits women with severe morning sickness

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Blocking specific protein increases vulnerability of tumors to treatment

Genomic tests increase accuracy of breast cancer diagnosis

Diabetes drug may improve ovarian cancer survival

Roundup: Fla. judge rules legislature must decide on prison care privatization; Skepticism over Ore. medical liability reform proposal

RedHill Biopharma completes $6.5M private placement

Targeted therapy as common as chemotherapy at end of life

Using Nanoparticles to Target Cancer

SLN surgery identifies whether breast cancer in lymph nodes remains after chemotherapy

Study provides important data about fertility window of women with childhood cancer

Nanoparticle-based drug delivery attacks cancer cells without harming normal ones

Researchers investigate GPER receptor as possible new drug target for breast cancer

Study calls for reform of Medicare reimbursement rates and hospice eligibility requirements

Combining 5-fluorouracil and IL-1 beta inhibitor can improve effectiveness of chemotherapy

Data from OncoSec Medical clinical studies to be presented at DNA Vaccines 2012 Conference

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Cancer Research - Second Edition eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Newsletters you may be interested in